After six years of existence and raising more than $20 million, Personal Genome Diagnostics has its first full-time CEO.
Douglas Ward will head the Canton-based Johns Hopkins spinout and sit on its board, the company announced Monday.
Ward has worked in medical diagnostics for 25 years, most recently serving as Vice President of Companion Diagnostics at Ventana Medical Systems. He has also worked at GE Healthcare and Bayer Healthcare.
Founded in 2010 by Hopkins cancer researchers Victor Velculescu and Luis Diaz, Personal Genome Diagnostics specializes in technology to assist cancer genome testing. The company closed a $21.4 million Series A led be NEA in 2015.
Personal Genome Diagnostics previously did not have a CEO. A spokeswoman said Ward is “expected to build on the company’s record of strong growth and provide experienced leadership for the further development of key product lines.”
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
Donate to the Journalism Fund
Your support powers our independent journalism. Unlike most business-media outlets, we don’t have a paywall. Instead, we count on your personal and organizational contributions.
These 10 regions could be most impacted by federal return-to-office mandates
From Belgaum to Baltimore and beyond, this founder leaned on family to build a biotech juggernaut
Tech-related orders and economic reorganizations hit Maryland. Here’s what they mean.
